ABBV - AbbVie-Genmab lymphoma drug gets FDA breakthrough designation
2023-11-27 08:03:06 ET
More on AbbVie, Genmab, etc.
- AbbVie Vs. Amgen: How Peter Lynch Picks Dividend Stocks
- Genmab A/S (GMAB) Q3 2023 Earnings Call Transcript
- Genmab A/S 2023 Q3 - Results - Earnings Call Presentation
- AbbVie suing Sandoz, four others to block generic Rinvoq: report
- AbbVie reports positive data for migraine drug candidate
For further details see:
AbbVie-Genmab lymphoma drug gets FDA breakthrough designation